文献速递肿瘤 PET/CT核素与放射性配体治疗

扩展淋巴结清扫术中应用[111In]PSMA-617术中检测PSMA-PET/CT阳性转移性前列腺癌淋巴结的结果

Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer.
PubMed 文献 · EJNMMI Res · 2020-03-06

23例PSMA-PET/CT可疑淋巴结转移的前列腺癌患者,术前48小时静脉注射[111In]PSMA-617,术中离体测量切除组织。肿瘤累及亚区γ探针中位数33.5 CPSnorm、锗探测器0.71 %IAlbm,均显著高于无肿瘤亚区的3.0 CPSnorm和0.03 %IAlbm(各p<0.0001)。

要点

  • 肿瘤累及与无肿瘤亚区的γ探针及锗探测器测量值差异显著(各p<0.0001)。
  • γ探针阈值CPSnorm>23时,真阳性64例、真阴性158例、假阴性39例、假阳性6例。
  • 锗探测器阈值%IAlbm>0.27时,真阳性74例、真阴性158例、假阴性30例、假阳性5例。

核心结论

  • [111In]PSMA-617用于淋巴结清扫术中γ探针实时检测肿瘤累及组织是可行的,γ探针结果可由锗探测器精确测量确认,且肿瘤累及与无肿瘤样本测量值显著不同。

研究设计与样本

  • 23例PSMA-PET/CT可疑淋巴结转移的前列腺癌患者(21例生化复发,2例初治),术前48小时静脉注射[111In]PSMA-617,切除组织样本(淋巴结、转移淋巴结及纤维脂肪组织)离体用γ探针测量CPSnorm,并用锗探测器测量%IAlbm验证,与组织病理学对照。

主要发现

  • 共从23例患者的275个亚区切除864枚淋巴结(197枚转移淋巴结),平均每例8.6±14.9枚转移淋巴结;275份组织样本中104份为癌。肿瘤累及亚区γ探针中位数33.5 CPSnorm、锗探测器0.71 %IAlbm,无肿瘤亚区分别为3.0 CPSnorm、0.03 %IAlbm(各p<0.0001)。

关键数值与推荐

  • 基于特异性>95%的临床要求选择阈值:γ探针CPSnorm>23时真阳性64例、真阴性158例、假阴性39例、假阳性6例;锗探测器%IAlbm>0.27时真阳性74例、真阴性158例、假阴性30例、假阳性5例。

临床怎么用

  • 作者认为[111In]PSMA-617用于淋巴结清扫术中γ探针实时检测肿瘤累及组织样本是可行的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617, referred to as [111In]PSMA-617) as a γ-emitting tracer for intraoperative γ-probe application for resected tissue samples in PCa patients. Forty-eight hours prior to LA, [111In]PSMA-617 was administered intravenously in 23 patients with suspected LNM on PSMA-PET/CT (n = 21 with biochemical relapse, n = 2 at primary therapy). Resected tissue samples (LN, LNM and fibrofatty tissue) were measured ex situ by a γ-probe expressed as counts per second (CPSnorm). [111In]PSMA-617 tissue sample uptake was measured by a germanium detector for verification and calculated as %IAlbm (percent injected activity per kilogram lean body mass at time of surgery). Based on a clinical requirement for a specificity > 95%, thresholds for both ex situ measurements were chosen accordingly. Correlation of the results from PET/CT, γ-probe and germanium detector with histopathology was done. RESULTS: Eight hundred sixty-four LNs (197 LNM) were removed from 275 subregions in 23 patients, on average 8.6 ± 14.9 LNM per patient. One hundred four of 275 tissue samples showed cancer. Median γ-probe and germanium detector results were significantly different between tumour-affected (33.5 CPSnorm, 0.71 %IAlbm) and tumour-free subregions (3.0 CPSnorm, 0.03 %IAlbm) (each p value < 0.0001). For the chosen γ-probe cut-off (CPSnorm > 23) and germanium detector cut-off (%IAlbm > 0.27), 64 and 74 true-positive and 158 true-negative samples for both measurements were identified. Thirty-nine and 30 false-negative and 6 and 5 false-positive tissue samples were identified by γ-probe and germanium detector measurements. CONCLUSION: [111In]PSMA-617 application for LA is feasible in terms of an intraoperative real-time measurement with a γ-probe for detection of tumour-affected tissue samples. γ-probe results can be confirmed by precise germanium detector measurements and were significantly different between tumour-affected and tumour-free samples.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Jilg CA, Reichel K, Stoykow C, et al. Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer. EJNMMI Res. 2020. PMID: 32144598. doi:10.1186/s13550-020-0598-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。